BXCL501, a dexmedetomidine sublingual film, is under FDA review for first-ever at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Acquisition adds differentiated late-stage investigational asset with potential to address a significant unmet need for patients Transaction supports Teva’s Pivot to Growth strategy and the […]
In a sitting room in Surulere in the second week of October 2026, a twenty-six-year-old with a first degree in microbiology read the same email four times before she called her mother in from the…
The agreement supports EyeLief® combination drug-device product development in anticipation of a future clinical program, with polymer supply also supporting OcuLief® and non-ocular applications…
